https://clinicaltrials.gov/ct2/show/NCT03899402
Triple Therapy in T1DM
Study Type : Interventional
Estimated Enrollment : 114 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This will be a two-center, randomized, open-label then double-blind, parallel group, placebo and standard of care controlled prospective study in type 1 diabetes.
Masking: Double (Participant, Investigator)
Masking Description: This will be a two-center, randomized, open-label then double-blind, parallel group, placebo and standard of care controlled prospective study in type 1 diabetes.
Primary Purpose: Treatment
Official Title: Triple Therapy for Type 1 Diabetes With Insulin, Semaglutide, and Dapagliflozin
Estimated Study Start Date : May 1, 2019
Estimated Primary Completion Date : May 1, 2022
Estimated Study Completion Date : May 1, 2022
